As of 2025-11-05, the EV/EBITDA ratio of Spero Therapeutics Inc (SPRO) is -1.83. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SPRO's latest enterprise value is 102.75 mil USD. SPRO's TTM EBITDA according to its financial statements is -56.28 mil USD. Dividing these 2 quantities gives us the above SPRO EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 12.4x - 14.9x | 13.6x |
| Forward P/E multiples | 13.5x - 20.3x | 16.9x |
| Fair Price | (12.95) - (14.35) | (14.72) |
| Upside | -643.9% - -702.8% | -718.5% |
| Date | EV/EBITDA |
| 2025-11-03 | -1.83 |
| 2025-10-31 | -1.88 |
| 2025-10-30 | -1.81 |
| 2025-10-29 | -1.78 |
| 2025-10-28 | -1.83 |
| 2025-10-27 | -1.74 |
| 2025-10-24 | -1.66 |
| 2025-10-23 | -1.65 |
| 2025-10-22 | -1.70 |
| 2025-10-21 | -1.82 |
| 2025-10-20 | -1.74 |
| 2025-10-17 | -1.66 |
| 2025-10-16 | -1.80 |
| 2025-10-15 | -1.94 |
| 2025-10-14 | -1.81 |
| 2025-10-13 | -1.74 |
| 2025-10-10 | -1.70 |
| 2025-10-09 | -1.81 |
| 2025-10-08 | -1.73 |
| 2025-10-07 | -1.61 |
| 2025-10-06 | -1.54 |
| 2025-10-03 | -1.50 |
| 2025-10-02 | -1.48 |
| 2025-10-01 | -1.41 |
| 2025-09-30 | -1.33 |
| 2025-09-29 | -1.35 |
| 2025-09-26 | -1.34 |
| 2025-09-25 | -1.39 |
| 2025-09-24 | -1.42 |
| 2025-09-23 | -1.46 |
| 2025-09-22 | -1.48 |
| 2025-09-19 | -1.45 |
| 2025-09-18 | -1.45 |
| 2025-09-17 | -1.35 |
| 2025-09-16 | -1.35 |
| 2025-09-15 | -1.33 |
| 2025-09-12 | -1.35 |
| 2025-09-11 | -1.40 |
| 2025-09-10 | -1.39 |
| 2025-09-09 | -1.43 |
| 2025-09-08 | -1.44 |
| 2025-09-05 | -1.60 |
| 2025-09-04 | -1.59 |
| 2025-09-03 | -1.53 |
| 2025-09-02 | -1.50 |
| 2025-08-29 | -1.52 |
| 2025-08-28 | -1.45 |
| 2025-08-27 | -1.43 |
| 2025-08-26 | -1.30 |
| 2025-08-25 | -1.30 |